title: Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia.
abstract: FLT3 is frequently mutated in acute myeloid leukemia (AML), but resistance has limited the benefit of tyrosine kinase inhibitors (TKI). We demonstrate that statins can impair FLT3 glycosylation, thus leading to loss of surface expression and induction of cell death, as well as mitigation of TKI resistance. Immunofluorescence microscopy confirms a reduction in surface localization and an increase in intracellular FLT3/internal tandem duplication (ITD) accumulation. This aberrant localization was associated with increased STAT5 activation but inhibition of both MAPK and AKT phosphorylation. Growth inhibition studies indicate that FLT3/ITD-expressing cells were killed with an IC(50) within a range of 0.2-2μM fluvastatin. Several mechanisms of resistance could be circumvented by fluvastatin treatment. An increase in the IC(50) for inhibition of phosphorylated FLT3/ITD by lestaurtinib caused by exogenous FLT3 ligand, resistance to sorafenib caused by the D835Y or FLT3/ITD N676K mutations, and activation of the IL-3 compensatory pathway were all negated by fluvastatin treatment. Finally, fluvastatin treatment in vivo reduced engraftment of BaF3 FLT3/ITD cells in Balb/c mice. These results demonstrate that statins, a class of drugs already approved by the US Food and Drug Administration, might be repurposed for the management of FLT3 mutant acute myeloid leukemia cases either alone or in conjunction with FLT3 TKI.
authors.affiliation: Departments of Oncology and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
authors.forename: Allen B
authors.initials: AB
authors.lastname: Williams
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.forename: Bao
authors.initials: B
authors.lastname: Nguyen
authors.forename: Patrick
authors.initials: P
authors.lastname: Brown
authors.forename: Mark
authors.initials: M
authors.lastname: Levis
authors.forename: Donald
authors.initials: D
authors.lastname: Small
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D049109:Cell Proliferation / Q000187:drug effects; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology*; D005260:Female; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D000077340:Fluvastatin; D006031:Glycosylation / Q000187:drug effects; D006801:Humans; D047468:Immunoprecipitation; D007211:Indoles / Q000494:pharmacology*; D007938:Leukemia / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality*; D051379:Mice; D008807:Mice, Inbred BALB C; D009154:Mutation / Q000187:drug effects*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D021381:Protein Transport; D015996:Survival Rate; D014407:Tumor Cells, Cultured; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics / Q000378:metabolism*
chemical_list: D000924:Anticholesteremic Agents; D005229:Fatty Acids, Monounsaturated; D007211:Indoles; D047428:Protein Kinase Inhibitors; D000077340:Fluvastatin; C497970:FLT3 protein, human; C497971:Flt3 protein, mouse; D051941:fms-Like Tyrosine Kinase 3